Skip to content
CompoundSci
All peptides
Research vial labelled Tirzepatide, a Incretin / GLP-1 class peptide studied in preclinical and clinical literature

Tirzepatide

GIP / GLP-1 dual agonist

Dual GIP and GLP-1 agonist with a full phase 3 programme in diabetes, obesity and sleep apnoea.

Large randomised trial evidence. Titration speed is the single biggest driver of the gastrointestinal side effect load.

General profile

Class
Incretin / GLP-1 class
Evidence
Strong human evidence
Studied dose range
2.5 mg titrating upward
Frequency in protocols
Weekly
Route
Subcutaneous
Half life
~5 days
Reconstitution
2 mL bacteriostatic water per 10 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Once weekly, same day each week

Five day half-life. Keep the weekday fixed and escalate slowly, since fast titration is what drives the gastrointestinal effects in the trials.

Reported cycle: 24 weeks on, run continuously in trials

The trials titrate over months and continue dosing, because discontinuation reliably produces regain.

Watch for: Persistent vomiting, upper abdominal pain radiating to the back, and muscle loss without resistance training.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    Tirzepatide + GLP-1 analogs

    Never run two incretin agonists together

    Both act on the GLP-1 receptor. Stacking them does not add benefit, it stacks the same gastric emptying delay and the same nausea, dehydration and gallbladder risk. Trials study one at a time for exactly this reason.

  • Hard stopTiming

    Tirzepatide + Retatrutide

    Never run two incretin agonists together

    Same receptor family, same side effect profile, no additional studied benefit. Choose one and titrate it slowly.

  • Separate syringesSame day fine, same syringe not

    Tirzepatide + Anything else, including another incretin

    Solo in the barrel, always

    Every incretin gets its own syringe and its own draw, including alongside another incretin. Protocol stacking is a real thing and is not a hard stop, but co-drawing is never part of it.

  • Pick oneSame day fine, same syringe not

    Tirzepatide + Another incretin in a designed protocol

    Stacking is a protocol decision, not redundancy

    Multi-incretin work uses different receptor balances, so it is not the same button pressed twice. It only makes sense with the job named first, each dose lowered against solo use, titration on response, protein defence and side effect monitoring. Insulin or sulfonylureas are physician territory.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Tirzepatide fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: Registrational trials with head-to-head comparisons against GLP-1 monotherapy.

Open questions: Long-term maintenance data is still accumulating, and the gastrointestinal side effect load is dose driven.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature